138 related articles for article (PubMed ID: 20840876)
1. Drug cost avoidance resulting from cancer clinical trials.
Bredin C; Eliasziw M; Syme R
Contemp Clin Trials; 2010 Nov; 31(6):524-9. PubMed ID: 20840876
[TBL] [Abstract][Full Text] [Related]
2. Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan.
Shen LJ; Chou H; Huang CF; Chou GM; Chan WK; Wu FL
Contemp Clin Trials; 2011 Jul; 32(4):485-91. PubMed ID: 21530679
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
4. Incremental drug treatment cost in HIV-positive patients in industry-sponsored clinical trials.
Perrín RS; López FJ
Ann Pharmacother; 2008 Nov; 42(11):1586-91. PubMed ID: 18780807
[TBL] [Abstract][Full Text] [Related]
5. Benefits of clinical pharmacy services in a community hospital.
Williams LE
Hosp Pharm; 1993 Aug; 28(8):759-63, 766-7. PubMed ID: 10127576
[TBL] [Abstract][Full Text] [Related]
6. Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M; Romero-Jiménez R; Herranz-Alonso A; Sánchez-Fresneda M; Gonzalez-Haba E; Collado-Borrel R; Benedi-González J; Sanjurjo-Sáez M
J Oncol Pharm Pract; 2019 Jul; 25(5):1099-1104. PubMed ID: 29792122
[TBL] [Abstract][Full Text] [Related]
7. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
8. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit.
Chuang LC; Sutton JD; Henderson GT
Hosp Pharm; 1994 Mar; 29(3):215-8, 221. PubMed ID: 10132696
[TBL] [Abstract][Full Text] [Related]
9. Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis.
Evans WK; Coyle D; Gafni A; Walker H;
Chronic Dis Can; 2003; 24(4):102-7. PubMed ID: 14733759
[TBL] [Abstract][Full Text] [Related]
10. Estimating per patient funding for cancer clinical trials: an Ontario based survey.
Wright JR; Roche K; Smuck B; Cormier J; Cecchetto S; Akow M; Pilatzke S; Pritchard KI
Contemp Clin Trials; 2005 Aug; 26(4):421-9. PubMed ID: 15925548
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and lung cancer clinical trials.
Du W; Reeves JH; Gadgeel S; Abrams J; Peters WP
Cancer; 2003 Oct; 98(7):1491-6. PubMed ID: 14508837
[TBL] [Abstract][Full Text] [Related]
12. Drug Cost Avoidance in Prostate Cancer Clinical Trials.
Calvin-Lamas M; Portela-Pereira P; Rabuñal-Alvarez MT; Martinez-Breijo S; Martín-Herranz MI; Gómez-Veiga F
Actas Urol Esp; 2015 Nov; 39(9):553-7. PubMed ID: 26071987
[TBL] [Abstract][Full Text] [Related]
13. Patient care contributions of clinical pharmacists in four ambulatory care clinics.
Hatoum HT; Witte KW; Hutchinson RA
Hosp Pharm; 1992 Mar; 27(3):203-6, 208-9. PubMed ID: 10116720
[TBL] [Abstract][Full Text] [Related]
14. Cost savings from dose rounding of biologic anticancer agents in adults.
Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
[TBL] [Abstract][Full Text] [Related]
15. Two methods for allocating pharmacy cost per patient case.
Pink GH; Bolley HB; Cockerill RW
Am J Hosp Pharm; 1994 May; 51(10):1331-4. PubMed ID: 8085571
[TBL] [Abstract][Full Text] [Related]
16. The Economic Contribution of Industry-Sponsored Pharmaceutical Clinical Trials.
Tran DT; Akpinar I; Fedorak R; Jonsson E; Mackey J; Richer L; Jacobs P
J Pharm Pharm Sci; 2017; 20(1):407-414. PubMed ID: 29197429
[TBL] [Abstract][Full Text] [Related]
17. The oncology impact of highly active antiretroviral therapy.
Schlichemeyer R; Chambers C; Gill MJ
J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
[TBL] [Abstract][Full Text] [Related]
19. Making or losing money with participation in clinical trials: a decision analysis.
Jacobs VR
Onkologie; 2009 Jul; 32(7):411-6. PubMed ID: 19556819
[TBL] [Abstract][Full Text] [Related]
20. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.
Aprikian AG; Fleshner N; Langleben A; Hames J
Can J Urol; 2003 Oct; 10(5):1986-94. PubMed ID: 14633326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
